RxDoctor Payments Data

Jeffrey Wenger, MD

Gastroenterology · West Palm Beach, FLNPI 1801898655

Payments from drug & device makers

$6,315in general payments, 2019–2025

Across 297 payments — averaging $21.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Takeda Pharmaceuticals U.S.A., Inc.$789
  • Johnson & Johnson$442
  • Janssen Scientific Affairs, LLC$370
  • Braintree Laboratories, Inc.$288
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$272
  • plus $2K from 24 others

What the payments were for

  • Food & beverage$6,20898%
  • Education$1062%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,315 in reported general payments places this provider in the 65th percentile of 1,388 gastroenterology providers in Florida.

See all gastroenterology providers in Florida

Medicare billing

Part B allowed, 2024
$368,182
Medicare patients
933
Services billed
4,976

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab24$686,886
LinzessLinaclotide79$64,562
CreonLipase/Protease/Amylase29$56,367
ClenpiqSod Picosulf/Mag Ox/Citric Ac310$53,284
Famotidine539$9,121
Pantoprazole Sodium558$8,213
Proctofoam-HcHydrocortisone/Pramoxine35$8,175
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates115$7,223
Mesalamine20$6,565
Dexlansoprazole DrDexlansoprazole13$3,869
CholestyramineCholestyramine (With Sugar)44$3,165
Budesonide DrBudesonide41$3,153
Omeprazole176$2,119
Dicyclomine Hcl63$1,052
Sucralfate25$1,001

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$442$686,88624 claims
AbbVieLinzess, Creon$1,802$120,929108 claims
Ferring Pharmaceuticals Inc.Clenpiq$210$53,284310 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,388 gastroenterology providers in Florida.

Other gastroenterology in West Palm Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →